Experience the power of an integrated approach to evidence-based research
Our vision is to revolutionize healthcare research and accelerate patient access to optimal care. By taking an integrated approach that leverages fit-for-purpose data, accelerated stakeholder insights, and flexible engagements, we offer the life sciences a better way to secure efficient, impactful evidence solutions.
Data Agnostic RWE
Asking the right questions and accessing all relevant evidence sources
From early development to commercialization, you need the best advice and optimal data sources to support your evidence needs. Our strategic, data-agnostic approach to real-world evidence leverages global datasets and expertise without limits.
Rapid stakeholder insights
Trust the voice of the stakeholder to test your evidence strategy and optimize market access
- Leverage our agile, tech-enabled RPR platform to develop robust market access strategies and fit-for-purpose evidence-generation plans.
- Secure critical payer, KOL, patient advocacy group, and policy maker insights across the product lifecycle.
- Engage with a global network of 3,000+ vetted stakeholders across 65+ countries to test your market access and evidence strategies as they evolve.
1000+ scientific publications
generated by our experts
|Title||GR Author(s)||Year||Therapeutic Area||Data Source||Journal/Conference||Full Citation & Links|
|Real-world characteristics of patients with wild-type transthyretin amyloid cardiomyopathy: an analysis of electronic healthcare records in the United States.||Crowley A, Benjumea D||2023||Cardiology||Optum EHR||American Journal of Cardiovascular Drugs||View|
|Benzodiazepine usage, healthcare resource utilization, and costs among older adults treated with common insomnia medications: a retrospective cohort study.||Amari DT||2023||Neurology||Marketscan Commercial and Medicare Supplemental||Clinicoeconomics and outcomes research||View|
|Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence.||Brown AE||2022||Oncology||n/a||Medical Oncology||View|
|Assessment of the relevance and credibility of indirect treatment comparisons to help inform health technology assessment and reimbursement decision-making: results of a 5-country payer survey.||Katsoulis I, Graham A||2023||General Medicine||RPR Survey||ISPOR Europe||View|
|Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment in Oncology.||Ignjatovic T||2023||Oncology||RPR Survey||ISPOR Europe||View|
“We are really impressed with the efficiency and quality of the work, your leadership skills, and the extra efforts you’ve made to ensure the results are absolutely accurate.”HEOR/RWE client
“Genesis Research Group is a valued, relied upon and trusted partner on our most important deliverables.”HEOR/RWE client
“Your culture of hiring and retaining good people provides stability and consistency.”HEOR/RWE client
“RPR… is my go-to resource to gain real-time insights from providers and payers on the value drivers for diagnostics across disparate care areas…”Head of Global Access, GE Healthcare